Erlangen

• A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended
  2023-509782-20-00 4 2021-11-11 Diffuse Cutaneous Systemic Sclerosis
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Gia … Ended
  2024-510744-31-00 5 2021-10-06 Giant cell arteritis (GCA)
• Study to investigate the efficacy and safety of allo-APZ2-CVU on wound healing of therapy-resistant chronic venous ulcer (CVU) Ended
  2023-510162-27-00 4 2021-08-18 Chronic venous ulcers (CVU)
• Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-P … Ended
  2023-509698-21-00 5 2021-03-17 Prevention of post abdominal surgery incisional infection.
• A Clinical Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Intravenous Induction Treatment Followed by Subcutaneous Ust … Ended
  2023-504977-19-00 5 2021-03-15 Moderately to Severely Active Ulcerative Colitis
• A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid Ended
  2024-510745-34-00 10 2020-11-11 Bullous Pemphigoid
• Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGROLT) Ended
  2023-509801-59-00 5 2020-07-09 Alopecia areata
• A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM) Ended
  2023-508293-28-00 5 2020-02-20 Dermatomyositis
• CIRCULATE Ended
  2023-506715-18-00 5 2019-12-04 colon cancer stage II, rectal cancer stage II
• A study to learn if Bimekizumab is safe and works over a long period in adults with Active Psoriatic Arthritis Ended
  2023-506528-95-00 5 2019-11-21 Psoriatic Arthritis
• Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended
  2022-500413-11-00 5 2019-06-17 Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC)
• A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli … Ended
  2022-501970-20-01 5 2019-06-07 Cis-eligible Muscle-invasive bladder cancer.
• A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati … Ended
  2023-508472-11-00 5 2018-06-13 Patients with early breast cancer
• A Trial to Determine the Safety of CC-93269, an Antibody, in People who have Multiple Myeloma That Has Returned After a Period of Treatment … Ended
  2023-506564-14-00 1 2018-05-16 Relapsed and refractory multiple myeloma (RRMM)
• Organ preservation in locally advanced rectal cancer by radiochemotherapy followed by consolidation chemotherapy. A prospective phase II pil … Ended
  2024-517928-19-00 4 2018-04-17 Male and female patients with histologically confirmed diagnosis of re
• Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of pr … Ended
  2023-510200-42-00 5 2017-12-06 primary sclerosing cholangitis (PSC)
• Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3 … Ended
  2022-501251-81-00 5 2017-06-08 Renal cell carcinoma
• A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended
  2022-501382-49-00 5 2017-03-07 Triple Negative Breast Cancer (TNBC)
• HD21 Ended
  2024-518022-33-00 5 2016-07-15 Advanced Stage of Hodgkin Lymphoma
• Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem … Ended
  2022-502040-13-00 4 High-risk Myelodysplastic neoplasia
• A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoria … Ended
  2023-508992-35-00 4 Plaque Psoriasis
• COMPRENDO - A PHASE II OPEN LABEL STUDY FOR THE COMPREHENSIVE ANALYSIS OF PREDICTORS OF THE TREATMENT WITH PEMBROLIZUMAB AND OLAPARIB IN PAT … Ended
  2024-519350-37-00 4 patients with unresectable or metastatic HER2 negative breast cancer a

Showing 361–382 of 382 trials